Tag: pulmonary embolism market growth

Uncover key drivers, emerging technologies, and competitive movements shaping the pulmonary embolism market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Pulmonary Embolism Market be in 2030 compared with 2026?

The pulmonary embolism market has experienced rapid expansion in recent years. It is projected to increase from $2.26 billion in 2025 to $2.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.0%. This historical growth can be attributed to a rise in cardiovascular and thromboembolic disorders, the expansion of hospital emergency care services, broader adoption of anticoagulant medications, increased understanding of pulmonary embolism symptoms, and the availability of sophisticated diagnostic imaging.

The pulmonary embolism market is anticipated to experience significant expansion over the next few years. It is projected to reach $4.14 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This growth during the forecast period can be ascribed to escalating investments in advanced anticoagulant drugs, the increasing uptake of catheter-based intervention techniques, the broadening of early diagnostic screening programs, a heightened focus on outpatient management strategies, and the rising demand for personalized cardiovascular care. Prominent trends for the forecast period include the increasing adoption of novel anticoagulant therapies, a growing utilization of minimally invasive thrombectomy devices, an intensified focus on early and accurate diagnosis, the expansion of integrated care pathways, and a stronger emphasis on risk stratification and prevention.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

What Drivers Are Guiding Growth Patterns In The Pulmonary Embolism Market?

The rising incidence of cancer is projected to boost the expansion of the pulmonary embolism market. Cancer encompasses various diseases marked by the uncontrolled and abnormal multiplication of cells within the body. A higher prevalence of cancer elevates the risk of blood clot formation, such as pulmonary embolism, in patients. This, in turn, fuels the demand for diagnostic tools and therapeutic solutions, including specialized pharmaceuticals. As an example, the American Cancer Society reported in January 2024 that the number of cancer cases in the US climbed to 2,001,140 from 1,958,310 in 2023, showing a 2.19% increase. Consequently, the growing prevalence of cancer is a significant factor driving the pulmonary embolism market’s growth.

How Is The Pulmonary Embolism Market Divided Into Segments?

The pulmonary embolism market covered in this report is segmented –

1) By Treatment: Medications, Mechanical Devices, Other Treatments

2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis

3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medications: Anticoagulants, Thrombolytics

2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy

3) By Other Treatments: Surgical Embolectomy, Supportive Care

Which Market Trends Are Opening Growth Opportunities In The Pulmonary Embolism Market?

Leading companies within the pulmonary embolism market are prioritizing the development of advanced products, such as the Triever16 Curve catheter and the RevCore thrombectomy catheter, to secure a competitive edge. For example, Inari Medical Inc., a US-based medical device company, introduced both the Triever16 Curve catheter and the RevCore thrombectomy catheter in June 2023. The innovative Triever16 Curve catheter is specifically engineered for peripheral thrombectomy and pulmonary embolism procedures, offering high trackability and a pre-shaped curve for focused aspiration. Its unique design also enables easy access to larger, more powerful 20F or 24F catheters. Concurrently, the RevCore thrombectomy catheter is devised for treating venous in-stent thrombosis, functioning as a mechanical thrombectomy device that utilizes a nitinol basket to capture and remove blood clots. Ultimately, these catheters are also instrumental in improving the safety and effectiveness of pulmonary embolism procedures.

Which Major Industry Participants Are Leading The Pulmonary Embolism Market Growth?

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson And Johnson Private Limited, F Hoffmann La Roche Ltd., Merck And Co Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK plc, Abbott Laboratories, AstraZeneca plc, Medtronic plc, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals plc, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd., CSL Behring GmbH, Grifols S.A., Octapharma AG, Kedrion S.p.A

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Pulmonary Embolism Market?

North America was the largest region in the pulmonary embolism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary embolism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pulmonary Embolism Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

Browse Through More Reports Similar to the Global Pulmonary Embolism Market 2026, By The Business Research Company

Embolization Coils Market Report 2026

https://www.thebusinessresearchcompany.com/report/embolization-coils-global-market-report

Vascular Embolization Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-embolization-global-market-report

Venous Thromboembolism Market Report 2026

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Pulmonary Embolism Market?

In recent years, the market size for pulmonary embolism has seen a rapid expansion. It is projected to increase from $2.03 billion in 2024 to $2.26 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.4%. This notable growth throughout the historical period can be credited to factors such as anticoagulant therapies, research and clinical trials, heightened awareness of pulmonary embolism, and vte prophylaxis.

Over the coming years, the pulmonary embolism market is projected to experience accelerated growth, reaching a value of $3.62 billion by 2029 with a compound annual growth rate (CAGR) of 12.5%. This growth anticipated throughout the forecast period shall be influenced by factors such as targeted therapies, telemedicine and remote monitoring, health equity initiatives, and global health schemes. The future market trends will be dominated by elements like application of artificial intelligence in diagnosis, novel anticoagulants, creation of pulmonary embolism response teams and a greater focus on patient-centered care.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

What Drivers Are Accelerating Expansion Of The Pulmonary Embolism Market?

The growth of the pulmonary embolism market is anticipated to be propelled by the increasing occurrence of blood clots. Blood clots, also referred to as thrombi, are gel-like or semi-solid masses that form inside blood vessels. Pulmonary embolism risk is increased by blood clots as they can prevent blood from flowing freely to the lungs. Ordinarily, these blood clots lead to blockages, often in the deep veins of the legs, which then heightens the risk of pulmonary embolism. This was evidenced in April 2022 when Gavi, the Vaccine Alliance, an international body aimed at enhancing access to vaccines for children that are new or underused, published an article stating that scientists had detected a 33-fold surge in the likelihood of potentially lethal lung clots and a five-fold increase in the risk of deep vein thrombosis in the 30 days subsequent to COVID-19 exposure. As a result, the growing occurrence of blood clots is fuelling the expansion of the pulmonary embolism market.

What Are The Primary Segmentation Parameters In The Pulmonary Embolism Market?

The pulmonary embolismmarket covered in this report is segmented –

1) By Treatment: Medications; Mechanical Devices; Other Treatments

2) By Diagnosis: Chest X-Ray; Electrocardiogram (ECG); Magnetic Resonance Imaging (MRI); Computed Tomography Scan; Pulmonary Angiography; Venography; Venous Ultrasound; D-Dimer Test; Other Diagnosis

3) By Symptoms: Shortness Of Breath; Chest Pain; Cough; Irregular Heartbeat; Dizziness; Fever; Cyanosis; Other Symptoms

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Medications: Anticoagulants; Thrombolytics

2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters; Catheter-Assisted Thrombectomy

3) By Other Treatments: Surgical Embolectomy; Supportive Care

How Are Market Trends Influencing Competition In The Pulmonary Embolism Market?

Leading businesses in the pulmonary embolism marketplace are concentrating their efforts on creating cutting-edge products like the Triever16 Curve catheter and the RevCore thrombectomy catheter to establish competitive superiority. To illustrate, in June 2023, Inari Medical Inc., a medical device establishment based in the United States, introduced both the Triever16 Curve catheter and the RevCore thrombectomy catheter. The groundbreaking Triever16 Curve catheter is designed specifically for peripheral thrombectomy and pulmonary embolism procedures, offering superior trackability and a curve pre-shaped for concentrated aspiration. The catheter also sports a distinctive design enabling easy transition to larger and stronger 20F or 24F catheters. The RevCore thrombectomy catheter is constructed for treating venous in-stent thrombosis and functions as a mechanical thrombectomy apparatus, utilizing a nitinol basket to ensnare and remove blood clots. Further, these catheters enhance the safety and efficacy of pulmonary embolism operations.

Which Players Are Shaping The Competitive Landscape Of The Pulmonary Embolism Market?

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

What Are The Emerging Regional Trends Driving The Pulmonary Embolism Market?

North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

Browse Through More Reports Similar to the Global Pulmonary Embolism Market 2025, By The Business Research Company

Cardiac Assist Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiac Rhythm Management Crm Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-rhythm-management-crm-devices-and-equipment-global-market-report

Cardiac Pacemakers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Pulmonary Embolism Market Between 2025 And 2029?

The pulmonary embolism market has experienced rapid expansion in recent years. This market is projected to expand from $2.03 billion in 2024 to reach $2.26 billion by 2025, driven by a compound annual growth rate (CAGR) of 11.4%. Historically, this growth can be linked to factors such as anticoagulant therapies, extensive research and clinical trials, heightened pulmonary embolism awareness, and effective VTE prophylaxis strategies.

The pulmonary embolism market size is projected to experience substantial expansion in the coming years. It is anticipated to reach $3.62 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.5%. This anticipated growth during the forecast period is due to factors such as targeted therapies, telemedicine and remote monitoring, health equity initiatives, and global health initiatives. Key developments expected over the forecast period encompass artificial intelligence in diagnosis, novel anticoagulants, pulmonary embolism response teams, and patient-centered care.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

What Are The Top Growth Drivers Impacting The Pulmonary Embolism Market Outlook?

The rising occurrence of blood clots is projected to fuel expansion in the pulmonary embolism market in the coming years. A blood clot, also referred to as a thrombus, is a semisolid or gel-like mass that develops inside a blood vessel. These clots elevate the likelihood of pulmonary embolism by hindering blood circulation to the lungs. Such blockages, frequently forming in the deep veins of the legs, consequently heighten the risk of pulmonary embolism. Illustratively, an article from April 2022, released by Gavi, the Vaccine Alliance, an international body dedicated to enhancing access to novel and underutilized vaccines for children, reported that within 30 days post-COVID-19 exposure, researchers observed a 33-fold surge in the probability of potentially lethal clots in the lungs and a five-fold increase in the danger of deep vein thrombosis. Consequently, the growing prevalence of blood clots is a key factor propelling the growth of the pulmonary embolism market.

What Are The Different Segment Classifications Within The Pulmonary Embolism Market?

The pulmonary embolismmarket covered in this report is segmented –

1) By Treatment: Medications; Mechanical Devices; Other Treatments

2) By Diagnosis: Chest X-Ray; Electrocardiogram (ECG); Magnetic Resonance Imaging (MRI); Computed Tomography Scan; Pulmonary Angiography; Venography; Venous Ultrasound; D-Dimer Test; Other Diagnosis

3) By Symptoms: Shortness Of Breath; Chest Pain; Cough; Irregular Heartbeat; Dizziness; Fever; Cyanosis; Other Symptoms

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Medications: Anticoagulants; Thrombolytics

2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters; Catheter-Assisted Thrombectomy

3) By Other Treatments: Surgical Embolectomy; Supportive Care

What Are The Major Trends Driving The Growth Of The Pulmonary Embolism Market?

Major companies within the pulmonary embolism market are actively focusing on developing innovative products like the Triever16 Curve catheter and the RevCore thrombectomy catheter to secure a competitive edge. For instance, in June 2023, Inari Medical Inc., a US-based medical device company, launched both the Triever16 Curve catheter and the RevCore thrombectomy catheter. This advanced Triever16 Curve catheter is specifically engineered for peripheral thrombectomy and pulmonary embolism procedures, boasting high trackability and a pre-shaped curve for focused aspiration. Its unique design also permits easy access for larger and more powerful 20F or 24F catheters. The RevCore thrombectomy catheter is designed to treat venous in-stent thrombosis and functions as a mechanical thrombectomy device utilizing a nitinol basket to capture and remove blood clots. Furthermore, these catheters enhance the safety and effectiveness of pulmonary embolism procedures.

Which Global Market Leaders Are Shaping The Future Of The Pulmonary Embolism Sector?

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Pulmonary Embolism Market?

North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Pulmonary Embolism Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

Browse Through More Reports Similar to the Global Pulmonary Embolism Market 2025, By The Business Research Company

Cardiac Assist Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiac Rhythm Management Crm Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-rhythm-management-crm-devices-and-equipment-global-market-report

Cardiac Pacemakers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Pulmonary Embolism Market from 2024 to 2025?

In recent years, the market size for pulmonary embolism has seen substantial expansion. The predicted growth is from $2.03 billion in 2024 to $2.27 billion in 2025, achieving a compound annual growth rate (CAGR) of 11.9%. The notable increase in the historic period can be linked to anticoagulant therapies, various research and clinical trials, heightened awareness of pulmonary embolism, and VTE prophylaxis.

What Is the Projected Market Size of the Pulmonary Embolism Market?

In the upcoming years, the market size for pulmonary embolism is projected to experience a swift expansion. The market value is anticipated to reach $3.63 billion in 2029, growing at a Compound Annual Growth Rate (CAGR) of 12.5%. The predicted growth in this period can be credited to a focus on targeted therapies, the augmenting role of telemedicine, and remote monitoring, with initiatives towards health equity and worldwide health contributing to this expansion. Some significant trends to watch during this forecast period include the implementation of artificial intelligence in diagnosis, the development of unique anticoagulants, the formation of pulmonary embolism response teams, and an increased emphasis on patient-oriented care.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

Who are the Major Competitors in the Pulmonary Embolism Market Outlook?

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

What Is Fueling Growth in the Pulmonary Embolism Market?

The growing occurrence of blood clots is predicted to fuel the expansion of the pulmonary embolism market. A blood clot or thrombus is a gelatinous or semisolid clot that forms inside a blood vessel. Such clots can precipitate a pulmonary embolism by hindering the blood flow to the lungs. The clot usually causes a blockage in the deep veins of the legs, consequently heightening the probability of a pulmonary embolism. For example, in April 2022, Gavi, the Vaccine Alliance, an international union established to enhance access to new and underused vaccines for children, published an article reporting a 33-fold increase in the likelihood of life-threatening lung clotting, and a 5-fold upsurge in the risk of deep vein thrombosis over 30 days post-COVID-19 exposure. Hence, the rising occurrence of blood clots is fueling the pulmonary embolism market’s growth. The escalation in cancer occurrences is anticipated to boost the growth of the pulmonary embolism market further. Cancer is a cluster of diseases marked by the unregulated and abnormal cell growth in our bodies. The rise in cancer incidences elevates the chances of clotting disorders like pulmonary embolism in cancer patients, thereby creating a higher demand for diagnostic tests and treatments, including specialized medications. For example, in January 2024, the American Cancer Society, a nonprofit US-based cancer advocacy group, reported an increase of 2.19% in cancer cases from 1,958,310 in 2023 to 2,001,140. Consequently, the rising prevalence of cancer is pushing the pulmonary embolism market higher.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

Which Pulmonary Embolism Market Segments Are Growing the Fastest?

The pulmonary embolism market covered in this report is segmented –

1) By Treatment: Medications, Mechanical Devices, Other Treatments

2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis

3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medications: Anticoagulants, Thrombolytics

2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy

3) By Other Treatments: Surgical Embolectomy, Supportive Care

Which Industry Trends Are Shaping the Future of the Pulmonary Embolism Market?

Leading businesses in the pulmonary embolism market are concentrating their efforts on creating unique products like the Triever16 Curve catheter and the RevCore thrombectomy catheter in the pursuit of a dominant position. For example, Inari Medical Inc., an American medical technology firm, inaugurated the Triever16 Curve catheter and the RevCore thrombectomy catheter in June 2023. The Triever16 Curve catheter, a groundbreaking product, is engineered for peripheral thrombectomy and pulmonary embolism operations, boasting superior trackability, a pre-shaped curve for dedicated aspiration, and a unique design that facilitates easy entry to larger and more effective 20F or 24F catheters. Consequently, the RevCore thrombectomy catheter is constructed to cure venous in-stent thrombosis, functioning as a mechanical thrombectomy device that employs a nitinol basket to trap and dispose of blood clots. In addition, these catheters enhance the safety and efficiency of pulmonary embolism procedures.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Which Countries Are Leading the Pulmonary Embolism Market?

North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13026

This Report Delivers Insight On:

1. How big is the pulmonary embolism market, and how is it changing globally?

2. Who are the major companies in the pulmonary embolism market, and how are they performing?

3. What are the key opportunities and risks in the pulmonary embolism market right now?

4. Which products or customer segments are growing the most in the pulmonary embolism market?

5. What factors are helping or slowing down the growth of the pulmonary embolism market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the pulmonary embolism industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Pulmonary Embolism Market In 2029?

The market for pulmonary embolism has seen swift growth in the past few years. It is predicted to rise from $2.03 billion in 2024 to $2.27 billion in 2025, with a compound annual growth rate (CAGR) of 11.9%. This growth during the historic period is credited to advances in anticoagulant therapies, extensive research and clinical trials, increased awareness of pulmonary embolism, and the use of vte prophylaxis.

In the coming years, the market size of pulmonary embolism is predicted to experience swift expansion. By 2029, it is projected to reach $3.63 billion with a 12.5% compound annual growth rate (CAGR). This anticipated rise during the forecast duration can be credited to factors such as targeted treatments, telemedicine and remote surveillance, health equality drives, and worldwide health campaigns. The prediction period will witness key trends including the integration of artificial intelligence in diagnosis, the use of new anticoagulants, pulmonary embolism response squads, and a greater focus on patient-driven care.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

Which Factors and External Forces Are Driving Demand in the Pulmonary Embolism Market?

The growth of the pulmonary embolism market is anticipated to be fueled by the escalating occurrence of blood clots. Blood clots, or thrombi, are semi-solid or gel-like formations in a blood vessel. They amplify the pulmonary embolism risk by hindering blood supply to the lungs. Often formed chiefly in the deep veins of the legs, blood clots heighten the likelihood of pulmonary embolism. As indicated in an April 2022 article by Gavi, the Vaccine Alliance – an international entity aimed at enhancing the accessibility of new and underutilized vaccines for kids – in the 30 days post-COVID-19 exposure, researchers found a 33-fold surge in the possibility of lethal lung clots and a five-fold uptick in the risk of deep vein thrombosis. Thus, the mounting incidence of blood clots is pushing the pulmonary embolism market’s growth. Driving the pulmonary embolism market is the growing prevalence of cancer. The term ‘cancer’ denotes diseases marked by abnormal, unregulated cell growth in the body. The rise in cancer cases boosts the chances of blood clots, like pulmonary embolism, especially among patients. This, in turn, drives demand for diagnostic procedures and treatments, including specialized drugs. For example, the American Cancer Society, a US-based nonprofit advocating for cancer, reported in January 2024 that cancer instances rose to 2,001,140 from 1,958,310 in 2023, indicating a 2.19% growth rate. Therefore, as cancer prevalence increases, it continues to fuel the expansion of the pulmonary embolism market.

Which Segments in the Pulmonary Embolism Offer the Most Growth?

The pulmonary embolism market covered in this report is segmented –

1) By Treatment: Medications, Mechanical Devices, Other Treatments

2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis

3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medications: Anticoagulants, Thrombolytics

2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy

3) By Other Treatments: Surgical Embolectomy, Supportive Care

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

What Are the Fastest-Growing Geographies in the Pulmonary Embolism Market?

North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Cutting-Edge Market Trends Are Expected to Drive thePulmonary Embolism Market’s Growth?

In the pulmonary embolism market, top-tier companies are concentrating their efforts on creating innovative products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter to stay competitive. For instance, the US-based medical device company, Inari Medical Inc., introduced the Triever16 Curve catheter and the RevCore thrombectomy catheter to the market in June 2023. The recently introduced Triever16 Curve catheter is specifically tailored for peripheral thrombectomy and pulmonary embolism processes. The key features of this catheter include excellent trackability and a pre-moulded curve for focused aspiration. Its unique design allows for easy access to larger and more robust 20F or 24F catheters. The RevCore thrombectomy catheter, on the other hand, targets the treatment of venous in-stent thrombosis. This mechanical thrombectomy device employs a nitinol basket to trap and remove blood clots. Furthermore, these catheters enhance the safety and efficacy of pulmonary embolism procedures.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

What Are the Key Elements That Define the Pulmonary Embolism Market?

A pulmonary embolism is a blockage in the pulmonary artery, which transports blood from the heart to the lungs. It causes the clot of blood that has gone to the lungs from another area of the body, most commonly the legs, which causes blockage. The symptoms of pulmonary embolism might range from abrupt shortness of breath to chest pain, coughing up blood or bloody mucus and others, depending on the severity of the clot.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13026

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of thePulmonary Embolism Market?

The escalating instances of blood clots are predicted to stimulate the expansion of the pulmonary embolism market. A blood clot, or thrombus, is characterized as a semi-solid or gel-like mass that develops within a blood vessel. These clots enhance the threat of pulmonary embolism by hindering the flow of blood to the lungs. A blood clot usually results in blockage, predominantly in the deep veins of the legs, thereby escalating the risk of pulmonary embolism. For example, in April 2022, Gavi, the Vaccine Alliance, an international organization established to broaden access to new and underutilized vaccines for children, cited in an article that scientists identified a 33-fold surge in the probability of lethal lung clots and a five-fold uptick in the risk of deep vein thrombosis within 30 days of exposure to COVID-19. Therefore, the rising instances of blood clots are promoting the expansion of the pulmonary embolism market. The Pulmonary Embolism Market Driver has identified that the escalating occurrence of cancer is fostering the growth of the pulmonary embolism market. Cancer comprises a set of diseases marked by unregulated and abnormal cell growth within the body. An upsurge in the prevalence of cancer elevates the threat of blood clots, including pulmonary embolism, among cancer patients. This results in an increased demand for diagnosis and treatments, inclusive of specialized medications. For example, in January 2024, the American Cancer Society, a United States-based nonprofit organization advocating for cancer, reported that the number of cancer cases had risen to 2,001,140 compared to 1,958,310 in 2023, indicating a growth of 2.19%. Hence, the escalating incidence of cancer is fostering the growth of the pulmonary embolism market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

#What is the Anticipated CAGR of thePulmonary Embolism Market, and What Factors Will Drive It?

The market size for pulmonary embolism has seen considerable growth in the recent past. It’s projected to increase from $2.03 billion in 2024 to $2.27 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.9%. The significant growth during the historic period is credited to the rise of anticoagulant therapies, research progress and clinical trials, increased understanding of pulmonary embolism, and vte prophylaxis.

The expected expansion rate for the pulmonary embolism market over the next few years is projected to be swift, with its worth estimated to reach $3.63 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.5%. The motivation behind this significant growth over the forecast period can be attributed to factors such as targeted therapies, the use of telemedicine and remote monitoring, initiatives promoting health equity, and international health campaigns. Additionally, key trends expected to emerge during the forecast window encompass the application of artificial intelligence in diagnostic procedures, the advent of novel anticoagulants, the establishment of pulmonary embolism response teams, and the implementation of patient-centered care models.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13026

Which Cutting-Edge Market Trends Are Expected to Drive thePulmonary Embolism Market’s Growth?

The pulmonary embolism market is dominated by leading corporations that are concentrating on the creation of groundbreaking products like the Triever16 Curve catheter and the RevCore thrombectomy catheter to gain a competitive edge. Inari Medical Inc., a medical device company based in the United States, took initiative in June 2023 by launching the Triever16 Curve catheter and the RevCore thrombectomy catheter. The Triever16 Curve catheter, a fresh concept, is built for peripheral thrombectomy and pulmonary embolism operations. The catheter is highly trackable, featuring a pre-shaped curve for concentrated aspiration and a distinctive design that makes it easy to use with larger and more potent 20F or 24F catheters. The RevCore thrombectomy catheter is tailored to treat venous in-stent thrombosis, boasting a mechanical thrombectomy device that employs a nitinol basket to trap and eradicate blood clots. Furthermore, these catheters enhance the safety and efficacy of pulmonary embolism procedures.

What Are the Leading Market Players Impacting thePulmonary Embolism Market’s Growth Trend?

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

How Are the Key Segments of the Pulmonary Embolism Market Driving Opportunities and Innovations?

The pulmonary embolism market covered in this report is segmented –

1) By Treatment: Medications, Mechanical Devices, Other Treatments

2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis

3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medications: Anticoagulants, Thrombolytics

2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy

3) By Other Treatments: Surgical Embolectomy, Supportive Care

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of thePulmonary Embolism Market?# Market Expansion?

North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Pulmonary Embolism Market 2025, By The Business Research Company:

Cardiac Marker Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-marker-global-market-report

Cardiac Assist Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiac Pacemakers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: